Opioid Use Trends in Cancer

Given the rapid pace of opioid-reduction efforts, there is an unmet need to understand the impact of these efforts on cancer patients for whom these medications may be intended or required. To address this knowledge gap, we propose the following project goals: (1) a population level analysis using SEER-Medicare to assess trends in receipt of new opioid use across strata of clinical appropriateness (patients with metastatic disease, patients undergoing surgery for early stage disease, and patients without cancer) and (2) an analysis of institutional data to assess trends in new opioid use across 3 distinct clinical scenarios (patients with metastatic disease, patients undergoing palliative radiotherapy, and patients undergoing surgery for early stage disease.

Funding source: U.S. Food and Drug Administration

Principal Investigator: Henry Park